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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a progressive, irreversible chronic inflammatory
disorder typified by increased recruitment of monocytes, lymphocytes and neutrophils. Because of this, as well as
the convenience of peripheral blood nuclear cells (PBMCs) assessments, miRNA profiling of PBMCs has drawn
increasing attention in recent years for various disease. Therefore, we analyzed miRNA and mRNA profiles to
understand their regulatory network between COPD subjects versus smokers without airflow limitation.
Methods: miRNA and mRNA profiling of PBMCs from pooled 17 smokers and 14 COPD subjects was detected
by high-throughput microarray. The expression of dysregulated miRNAs were validated by q-PCR. The miRNA
targets in dysregulated mRNAs were predicted and the pathway enrichment was analyzed.
Results: miRNA microarray showed that 8 miRNAs were up-regulated and 3 miRNAs were down-regulated in
COPD subjects compared with smokers; the upregulation of miR-24-3p, miR-93-5p, miR-320a and miR-320b and
the downregulation of miR-1273 g-3p were then validated. Bioinformatic analysis of regulatory network between
miRNA and mRNA showed that NOD and TLR were the most enriched pathways. miR-24-3p was predicted to regulate
IL-18, IL-1β, TNF, CCL3 and CCL4 and miR-93-5p to regulate IκBα.
Conclusions: The expression of miRNA and mRNA were dysregulated in PBMCs of COPD patients compared with
smokers without airflow limitation. The regulation network between the dysregulated miRNA and mRNA may provide
potential therapeutic targets for COPD.
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Background
Chronic obstructive pulmonary disease (COPD) is a
progressive, irreversible chronic inflammatory disorder.
Caused predominantly by cigarette smoking, COPD is
one of the leading causes of mortality globally [1].
Although cigarette smoking is the major cause of
COPD, there is currently no satisfactory therapy to
treat individuals once the disease is established. Inflam-
mation plays a pivotal role in the disease process, with
CD8+ T lymphocytes, neutrophils and macrophages be-
ing the main type of immune cells of local inflamma-
tory milieu of COPD [2]. Different immunoregulatory
properties of T cells and monocytes have been demon-
strated in COPD patients [3], and the inflammatory re-
sponse in the lungs of COPD patients is strongly linked
to tissue destruction and alveolar airspace enlargement
[4], in part due to the loss of lung structural cells due
to heightened apoptosis.
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microRNAs (miRNAs) are a growing family of small
non-coding RNAs (approximately 19 to 25 nucleotides
long) with a regulatory function on gene expression [5].
Through binding to the 3′ untranslated region (3′ UTR)
of target messenger RNAs, miRNAs can lead to direct
inhibition of protein translation or degradation of mes-
senger RNA [5]. In addition, miRNAs can alter gene ex-
pression by targeting transcription factors and DNA
methyltransferases. In this way, miRNAs work as post-
transcriptional regulators of gene expression and control
various cellular processes such as differentiation, prolif-
eration, and cell-cell interaction. The dysregulation of
miRNAs is linked to a wide spectrum of diseases, includ-
ing proliferative vascular disease, cardiac disorders, lung
diseases, kidney diseases, diabetes mellitus, fibrosis and
cancer [6–8].
A few studies have been conducted to reveal the dys-
regulation and role of miRNAs in COPD. Ezzie et al.
[9] compared the miRNA expression in lung tissue de-
rived from smokers with and without COPD and iden-
tified 70 differentially expressed miRNAs. A report by
Pottelberge et al. [10] demonstrated that 34 miRNAs
were differentially expressed between never-smokers
and current smokers without airflow limitation, and 8
miRNAs were expressed at a significantly lower level in
current-smoking patients with COPD compared with
never-smokers without airflow limitation. Another
study showed that microRNA-34c is associated with
emphysema severity in COPD [11]. Sato et al. [12] ob-
served reduced miR-146a expression in lung fibroblasts
of patients with COPD and showed that miR-146a defi-
ciency increased the expression of PGE2 through de-
pression of the miR-146a target COX-2. Finally, Lewis
et al. [13] found downregulated miR-1 expression in
quadriceps muscles and speculated that this is linked to
the muscle weakness observed in COPD.
On account of the convenience of peripheral blood
nuclear cells (PBMC) assessments, the miRNA profiling
of PBMC has drawn increasing attention in recent years
in various diseases such as cancer [14, 15], Alzheimer’s
Disease [16], diabetes [17] and autoimmune disease [18].
However, there is no report regarding miRNA expres-
sion profiles of PBMC in COPD patients. Therefore, in
this study, we sought to determine if miRNAs were dif-
ferentially expressed in PBMCs of COPD patients and
if miRNA expression may be linked to dysregulated
mRNA expression relevant to the pathogenesis of
COPD. We analyzed miRNA and mRNA expression
profiles in PBMCs from COPD patients versus smokers
without airflow limitation. The mRNA targets of the
dysregulated miRNA were predicted and pathway en-
richment was analyzed. We identified a signature of
COPD-associated miRNA, such that miR-24-3p, miR-
93-5p, miR-320a, miR-320b and miR-1273g-3p were
significantly dysregulated in COPD patients. Bioinfor-
matic analysis between miRNA and predicted mRNA
showed that NOD and TLR were the most enriched
pathways. In NOD pathway, miR-24-3p was predicted
to regulate IL18/IL1B/TNF, and miR-93-5p to regulate
NLRP3/IL6/NFKBIA. In TLR pathway, miR-24-3p was
predicted to regulate CCL3/CCL4/IL1B/TNF, and miR-
93-5p to regulate IL6/CXCL10/NFKBIA.
Methods
Subjects
Peripheral venous blood was taken in heparin-coated
tubes from 17 smokers without airflow limitation and 14
COPD subjects at Department of Respiration, The First
Affiliated Hospital, Xi’an Jiaotong University, Xi’an,
China. COPD subjects were eligible for this study if
they met the following criteria: age ≥ 50 and ≤76 years;
smoking history (≥20 pack-years); post-bronchodilator
FEV1 ≥ 25% of predicted value and post-bronchodilator
FEV1/forced vital capacity (FVC) ≤ 0.70; no history of
asthma, atopy (as assessed by an allergy skin prick test
during screening) or any other active lung disease. Pa-
tients on home oxygen or with raised carbon dioxide
tension (>44 mmHg), α1-antitrypsin deficiency, recent
exacerbation (in the last 4 weeks), an uncontrolled
medical condition or hypersensitivity to inhaled corti-
costeroids and bronchodilators were not eligible for the
study. All smokers without airflow limitation met the fol-
lowing criteria: age ≥ 42 and ≤75 years, Post-BD FEV1%
predicted >80, no diagnostic cancer, diabetes, cardiovascu-
lar disease and hypertension, no use of inhaled or oral cor-
ticosteroids in the previous 6 months, no atopy, and no
respiratory tract infection 1 month prior to the study.
Patient characteristics are in Table 1. The experimen-
tal procedures were performed with ethical approval
from the Research Ethics Boards of The First Affiliated
Hospital, Xi’an Jiaotong University (2015–015).
Table 1 Clinical characteristics of smokers without airflow
limitation and COPD patients
Smokers COPD
Number 17 14
Age 56 ± 17 69 ± 8
Male/Female 17/0 13/1
Current/ex-smokers 14/3 8/6
Pack-years 23 ± 3 27 ± 6





Data are presented as Means ± SD. BD bronchodilator, FEV1 forced expiratory
volume in 1 s
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PBMC isolation and RNA extraction
PBMCs were isolated from venous blood by density
gradient centrifugation over Ficoll-Paque PLUS reagent
(GE Healthcare, Uppsala, Sweden) and suspended in
QIAzol Lysis Reagent (Qiagen, Dusseldorf, Germany).
Total RNA was extracted using miRNeasy Mini Kit
(Qiagen) according to the manufacturer’s procedure.
RNA integrity was determined by formaldehyde de-
naturing gel electrophoresis.
miRNA and gene expression microarray
Equal amount of RNA sample from each smokers (N = 17)
and COPD patients (N = 14) was pooled respectively for
miRNA profiling assay using Affymetrix GeneChip
miRNA Array v.4.0 (Affymetrix, Santa Clara, CA, USA)
by Capitalbiotech company, Beijing, China. Briefly, after
labeled with Biotin, the total RNA was subsequently hy-
bridized overnight. The GeneChip® miRNA 4.0 arrays,
containing 30,424 total mature miRNA probe sets in-
cluding 2,588 mature human miRNAs and miRNAs of
202 other organisms, were washed and stained using
the Affymetrix GeneChip Hybridization Wash and
Stain Kit and were then scanned with the Affymetrix
GeneChip® Scanner 3000 (Affymetrix, Santa Clara, CA,
USA).
Messenger RNA microarray
Samples were prepared for mRNA microarray analysis
using Agilent Human Gene Expression Microarray
V4.0 (Santa Clara, California, USA). Hybridized slides
were then washed and scanned with Agilent Microarray
Scanner System (G2565CA).
Data analysis
The miRNA and mRNA array data were analyzed for
data summarization, normalization and quality control
using GeneSpring V11.5 software (Agilent). To select
differentially expressed genes, we used threshold values
of >2 fold change. The data were Log2 transformed and
median centred by genes using the Adjust Data function
of CLUSTER 3.0 software. Further analysis was per-
formed by hierarchical clustering with average linkages.
Finally, we performed tree visualization using Java Tree-
view (Stanford University School of Medicine, Stanford,
CA, USA).
Quantitative reverse transcription PCR validation
Independent assays were performed using quantitative
reverse transcription PCR (qRT-PCR) on all patient
samples for individual miRNA (miR-24-3p, miR-93-5p,
miR-320a, miR-320b, miR-191-5p, let-7b-5p, miR-342-
3p, miR-92a-3p, miR-3613-3p, miR-1273 g-3p and miR-
4668-5p) (Qiagen) and predicted target genes (IL18,
IL1B, TNF, CCL3, CCL4, NLRP3, IL6, NFKBIA and
CXCL10) (Bio-rad, Foster city, USA). In addition, the
expression of miR-24-3p, miR-93-5p, miR-320a, miR-
320b and miR-1273 g-3p was detected on the isolated
different cell types including CD4+ T cells, CD8+ T
cells, CD20+ B cells and CD14+ monocytes from
PBMCs in some COPD patients by positive selection
(Anti-PE MicroBeads UltraPure, Miltenyi Biotec,
Teterow, Germany). Data were presented relative to U6
for miRNA and β-actin for target genes based on calcu-
lations of 2(−σσCt). The primer sequences for target
genes were listed in Table 2. Statistical significance was
defined as p < 0.05 as measured by the t test using
GraphPad Prism 5 software (GraphPad, San Diego, CA,
USA).
Target prediction and network analysis
The target genes for miRNAs were predicted using mi-
Randa, MirTarget2, PicTar, PITA and TargetScan. The
regulation network diagram between miRNAs and
mRNAs was generated using Cytoscape. Based on the
data of mRNA array, the predicted target genes that
negatively regulated by the validated dysregulated miR-
NAs were selected for the further pathway enrichment
analysis. The DAVID [19] online analysis tool was used
and the significant enrichment threshold was P value of
Modified Fisher exact less than 0.05 and enriched gene
count more than 2.
Table 2 The sequence of primers for real-time PCR
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Results
MicroRNAs are dysregulated in PBMCs of COPD patients
We investigated the miRNA profiling in pooled PBMCs
from 17 smokers without airflow limitation and 14
COPD patients (Fig. 1). Compared with smokers, there
were 103 up-regulated and 34 down-regulated miRNAs
in COPD patients. We selected the dysregulated miR-
NAs with differences in the fluorescence intensity higher
than 1000 between the smokers and COPD patients. As
shown in Table 3, there were a total of 8 up-regulated
and 3 down-regulated miRNA; these were selected for
the further validation and analysis.
Validation of dysregulated miRNAs in PBMCs of COPD
patients
Among the selected 11 dysregulated miRNAs in COPD
patients versus smokers, we validated the expression of
5 miRNAs (miR-24-3p, miR-93-5p, miR-320a, miR-320b
and miR-1273 g-3p) in smokers and COPD patients by
qRT-PCR, as shown in Fig. 2a. MiR-1273 g-3p was the
most highly expressed miRNA in PBMCs of smokers,
while miR-320a and miR-320b had the higher relative
abundance in PBMCs of COPD patients (Fig. 2b). The
correlation analysis between miRNA expression and
FEV1% predicted showed that significant negative rele-
vance appeared in the expression of miR-24-3p, miR-
320a and miR-320b and positive relevance appeared in
miR-1273 g-3p (Fig. 2c). However, there is no difference
in miRNA sets between ex- and current smokers in the
smokers and COPD groups.
Verification of expression of dysregulated miRNAs in
different cell types of PBMCs
PBMCs consist mainly of T lymphocytes, B lymphocytes
and monocytes. We therefore analyzed the expression of
dysregulated miRNAs in the isolated different cell types
including CD4+ T cells, CD8+ T cells, CD20+ B cells and
CD14+ monocytes from PBMCs of smokers and COPD
patients. MiR-24-3p was consistently expressed higher in
monocytes. In smokers, miR-93-5p was mainly expressed
Fig. 1 Hierarchical clustering and scatter plot result of differentially expressed miRNAs in PBMCs from smokers and COPD patients. a Hierarchical
clustering image of miRNA expression of pooled RNA samples from PBMCs of COPD patients compared to smokers without airflow limitation.
b Scatter plot of miRNA expression of PBMCs of COPD patients compared to smokers without airflow limitation. Red and green colored dots
represent up- and down- regulated miRNAs in scatter plot, respectively
Table 3 Selected dysregulated miRNAs in COPD patients
compared with smokers without COPD
Upregulation Downregulation
miRNA Fold change miRNA Fold change
hsa-miR-24-3p 9.80 hsa-miR-3613-3p 0.14
hsa-miR-93-5p 9.73 hsa-miR-1273 g-3p 0.16






The miRNAs with difference of fluorescence intensity higher than 1000
was selected
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Fig. 2 (See legend on next page.)
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in monocytes, while it was equally expressed in CD4+
T cells, CD8+ T cells and monocytes in COPD patients.
CD8+ T cells mainly contribute to the increased expression
of miR-320a and miR-320b in COPD patients. In COPD
patients, more miR-1273 g-3p was expressed in monocytes,
suggesting that the expression was decreased in CD4+ T
cells, CD8+ T cells and CD20+ B cells in COPD (Fig. 3).
mRNAs are dysregulated in PBMCs of COPD patients
We performed a parallel mRNA microarray study to
compare the mRNA expression between the smokers
and COPD patients. The results revealed a total of 1508
genes that differed in expression between the two groups
(fold change >2; Fig. 4), where 164 mRNAs were up-
regulated and 137 were down-regulated when filtered by
(See figure on previous page.)
Fig. 2 Validation of differentially expressed miRNAs. a Expression of selected miRNAs in PBMCs of smokers and COPD patients. qRT-PCR was
performed on the same RNA samples (17smokers and 14 COPD patients) as microarray analysis. Data are presented as 2(−σσCt) relative to U6.
*P < 0.05, **P < 0.01 compared with smokers by Mann Whitney U test. b Relative abundance of differentially expressed miRNAs in PBMCs of
smokers and COPD patients. *P < 0.05, **P < 0.01 compared with smokers. c Correlation analysis between miRNA expression and FEV1% predicted
Fig. 3 Expression of miRNAs in the isolated different cell types of PBMCs from smokers (a) and COPD patients (b). The expression of miR-24-3p,
miR-93-5p, miR-320a, miR-320b and miR-1273g-3p was examined by qRT-PCR on CD4+ T lymphocytes, CD8+ T lymphocytes, CD20+ B lymphocytes
and CD14+ monocytes from smokers and COPD patients. Data are presented as 2(−σσCt) relative to β-actin
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fluorescence intensity difference higher than 1000.
Table 4 shows the 20 genes with the largest fold changes
and their known biological functions.
Regulation network of dysregulated miRNAs and mRNAs
Based on the genes negatively correlated with miRNAs
from microarray, the predicted regulatory network be-
tween the dysregulated miRNAs (that were validated)
and mRNAs in COPD patients was then analyzed (Fig. 5,
Table 5). The KEGG pathway enrichment analysis indi-
cated that the NOD − like receptor (NLR) and Toll − like
receptor (TLR) signaling pathway relevant to the patho-
genesis of COPD were significantly enriched (Fig. 6).
The involved genes include IL18/IL1B/TNF predicted to
be regulated by miR-24-3p, and NLRP3/IL6/NFKBIA by
miR-93-5p for NLR pathway. The genes CCL3/CCL4/
IL1B/TNF were predicted to be regulated by miR-24-3p,
and IL6/CXCL10/NFKBIA by miR-93-5p for TLR path-
way. The expression level of relevant predicted target
genes of individual subjects were further validated by
qRT-PCR. As shown in Fig. 7, the expression of IL18,
IL1B, TNF, NFKBIA, CCL3 and CCL4 was validated, but
not for NLRP3, IL6 and CXLC10.
Discussion
MicroRNAs play important regulatory roles in cell dif-
ferentiation, cell cycle and apoptosis. Due to the role of
multiple gene regulation, miRNAs have received much
attention as biomarkers and target for novel therapeu-
tics. In COPD therefore, the role of miRNAs in disease
pathogenesis is an attractive area of research. For the
first time, we conducted a comprehensive analysis of
both miRNA and mRNA expression in PBMCs from
subjects with COPD and compared their expression pro-
files to smokers without airflow limitation. We identified
137 differentially-expressed miRNAs in PBMCs from
COPD subjects compared with smokers without COPD.
Among the selected 11 miRNAs, the dysregulated ex-
pression of 5 miRNAs including miR-24-3p, miR-93-5p,
miR-320a, miR-320b and miR-1273g-3p were validated
by qPCR.
Of the miRNA investigated in this study, miR-24-3p is
of considerable interest. It has been reported that miR-
24-3p was consistently upregulated during terminal dif-
ferentiation of hematopoietic cells into a variety of line-
ages as well as during muscle and neuronal cell
differentiation [20, 21]. MiR-24-3p might also function
in cell proliferation [22, 23]. Upregulation of miR-24 is
associated with a decreased DNA damage response upon
etoposide treatment in highly differentiated CD8+ T cells
[24], and miR-24 is a negative regulator of classical
macrophage activation by LPS [25]. In this study, we
found increased expression of miR-24-3p mainly in the
T lymphocytes and monocytes, which might in part
Fig. 4 Hierarchical clustering and scatter plot result of differentially expressed mRNAs in PBMCs from smokers and COPD patients. a Hierarchical
clustering image of mRNA expression of pooled RNA samples from PBMCs of COPD patients compared to smokers without airflow limitation.
b Scatter plot of mRNA expression of PBMCs of COPD patients compared to smokers without airflow limitation. Red and green colored dots
represent up- and down- regulated mRNAs in scatter plot, respectively
Dang et al. Respiratory Research  (2017) 18:4 Page 7 of 13
contribute to the increased number of CD8+ T cells in
the lung [26] and to the impairment of host defenses in
the lower respiratory tract due to the smoke related
changes in the phenotype of alveolar macrophages of
COPD patients [27].
As for the rest of dysregulated miRNAs reported in
this study, we did not find the relevant evidences involv-
ing the pathogenesis of COPD, which implies the dis-
crepancy of the miRNA profile between PBMCs and
lung tissues. These miRNAs were mainly found dysregu-
lated in cancers and other disorders like autoimmune
diseases. For example, miR-93-5p was identified as a po-
tential biomarker of various types of cancer such as
acute myeloid leukemia [28] and laryngeal squamous cell
carcinoma [29]. This could be due to the link between
miR-93 and promotion of tumor growth, angiogenesis
and metastasis [30, 31]. miR-93 is up-regulated in
PBMCs from adult T-cell leukemia patients, and sup-
presses the expression of a tumor suppressor protein,
tumor protein 53-induced nuclear protein 1 (TP53INP1)
[32]. Four different transcripts have been reported in the
database for miR-320 (miR-320a, b, c, and d) [33]. The
seed region considered crucial for target binding remains
the same for miR-320a, b, c, and d. The plasma level of
miR-320a was found increased in patients with systemic
lupus erythematosus (SLE) [34], and miR-320-3p is in-
creased in the plasma of non-small cell lung cancer
(NSCLC) patients [35]. The expression of miR-1273g-3p
was found remarkably changed in Human Umbilical
Vein Endothelial Cells (HUVECs) under acute glucose
fluctuations, which was demonstrated to contribute to
endothelial dysfunction and autophagy [36]. MiR-1273
expression is also increased in the pancreas of mouse
model of pancreatic cancer [37].
By analyzing the regulation network between the dys-
regulated miRNA and mRNA, we predicted the negative
regulatory role of miRNAs on a total of 36 over
expressed and 61 under expressed mRNAs. The KEGG
pathway enrichment analysis indicated that the NOD −
like receptor (NLR) signaling pathway and Toll − like re-
ceptor (TLR) signaling pathway are the top 2 pathways
likely involved in the pathogenesis of COPD, with mir-
24-3p and miR-93-5p being predicted to regulate the
relevant genes in both pathways. As down-stream factors
of the NLR and TLR pathway, the mRNA levels of pro-
inflammatory mediators including IL-18, IL-1β, CCL3,
Table 4 Top 10 dysregulated mRNAs in COPD patients compared with smokers without COPD




CD177 CD177 molecule 22.59 Leukocyte migration
MUC17 Mucin 17, cell surface associated 21.54 Extracellular matrix constituent
IL1R2 Interleukin 1 receptor, type II 10.96 Decoy receptor, inhibits the activity of IL-1
SARDH Sarcosine dehydrogenase 9.52 Mitochondrial matrix
EGR3 Early growth response 3 6.75 Positive regulation of endothelial cell proliferation
AREG Amphiregulin 6.16 EGF family, promote the growth of normal epithelial cells
SLC6A2 Solute carrier family 6
(neurotransmitter transporter, noradrenalin), member 2
4.70 Sodium symporter
TMEM167A Transmembrane protein 167A 4.55 Golgi apparatus
KCNJ15 Potassium inwardly-rectifying channel, subfamily J,
member 15
4.42 Potassium channel activity
FCHO1 FCH domain only 1 4.39 Clathrin-mediated endocytosis
Downregulation
IL1A Interleukin 1, alpha −44.69 Immune response
IL6 Interleukin 6 (interferon, beta 2) −16.14 Pro-inflammatory and anti-inflammatory role
CXCL10 Chemokine (C-X-C motif) ligand 10 −15.08 leukocyte chemotaxis
TNF Tumor necrosis factor −11.79 Inflammation, cause apoptosis
CCL20 Chemokine (C-C motif) ligand 20 −7.94 Lymphocytes chemotaxis
CCL4 Chemokine (C-C motif) ligand 4 −6.19 Leukocyte chemotaxis
CCL3L3 Chemokine (C-C motif) ligand 3-like 3 −5.28 Leukocyte chemotaxis
C9orf7 Chromosome 9 open reading frame 7 −5.23 Calcium channel activity
IL1RN Interleukin 1 receptor antagonist −4.69 Inhibition of the activities of IL-1
RNF19B Ring finger protein 19B −4.17 Cytotoxic effects of natural killer (NK) cells
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CCL4, and TNF were found down-regulated in PBMCs
of COPD patients in this study. To the best of our
knowledge, the down-regulation of these mRNAs in
PBMCs of COPD patients has not been previously re-
ported. In fact, a previous study performed on human
peripheral lung tissue obtained from non-smokers,
smokers and COPD patients revealed the similar trends
of expression level of pro-inflammatory mediators,
where the level of IL-8, IL-6, IL-1β and TNF-α showed
the decreased trend in COPD patients compared with
smokers [38]. Instead, most previous studies showed ele-
vated expression levels of these mediators in serum or
lung [39]. We suspect that certain changes in the cyto-
kine expression profile may happen when the peripheral
immune cells infiltrate the local inflammatory sites in
the lung. The reduced expression of TLR2 has been
found in the alveolar macrophages of smokers and
COPD patients, which was associated with the impair-
ment of host defenses in the lower respiratory tract [27].
Furthermore, decreased cytokine and chemokine mRNA
expression in bronchoalveolar lavage cells from asymp-
tomatic smokers has been reported [40].
In addition, NFKBIA predicted to be regulated by
miR-93-5p- was the other down-regulated gene involved
in enriched pathways. In unstimulated cells, NF-κB is
found in the cytoplasm in an inactive non-DNA binding
form, associated with its inhibitory protein κBα (IκBα,
coded by NFKBIA gene), IκBα degradation unmasks the
nuclear localization signal present in NF-κB, allowing it
to enter the nucleus, bind DNA, and initiate gene tran-
scription [41]. In the present study, the down-regulation
of IκBα supposedly trigger the activation of NF-κB,
whose expression was also higher in PBMCs of COPD
patients. The coexistence of decreased level of IκBα and
pro-inflammatory mediators in COPD patients was also
reported on lung tissue [38]. Besides trigging the expres-
sion of pro-inflammatory mediators, NF-κB activation
may also be related with the disordered apoptosis of T-
cell hybridoma cell line [42]. Thus, the decreased ex-
pression of IκBα may contribute to the dysregulated
apoptosis of T cells in COPD [43].
Overall, through miRNAs and mRNAs expression pro-
filing in smokers and COPD patients, we identified the
dysregulated miRNAs and mRNAs in PBMCs from
COPD patients. We further analyzed the regulation net-
work between miRNA and mRNA, where NLR and TLR
was the most enriched pathways. Among them the
regulation of IL-18, IL-1β, TNF, CCL3 and CCL4 by
miR-24-3p, and IκBα by miR-93-5p may provide the
clue for potential investigations.
Conclusions
The expression of miRNA and mRNA were dysregulated
in PBMCs of COPD patients compared with smokers
without airflow limitation. The regulation network be-
tween the dysregulated miRNA and mRNA may provide
potential therapeutic targets for COPD.
Fig. 5 Regulation network between miRNAs and mRNAs. The negatively regulation of miRNA on dysregulated mRNAs was predicted and the
regulation network was drawn by using Cytoscape software. Red and green color represents up- and down-regulated genes, respectively
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Table 5 The pathway enrichment of dysregulated mRNAs regulated by miRNAs
miRNA Pathway Genes Gene Ratio P Value
miR-24-3p Rheumatoid arthritis IL1A/CCL3/CCL3L3/IL18/IL1B/TNF 6/16 2.37E-06
African trypanosomiasis HBA2/IL18/IL1B/TNF 4/16 2.47E-05
Cytokine-cytokine receptor interaction IL1A/CCL3/CCL4/CCL3L3/IL18/IL1B/TNF 7/16 2.53E-05
Malaria HBA2/IL18/IL1B/TNF 4/16 5.74E-05
Toll-like receptor signaling pathway CCL3/CCL4/IL1B/TNF 4/16 0.000645
Chagas disease (American trypanosomiasis) CCL3/CCL3L3/IL1B/TNF 4/16 0.000645
Graft-versus-host disease IL1A/IL1B/TNF 3/16 0.000741
Type I diabetes mellitus IL1A/IL1B/TNF 3/16 0.000743
Cytosolic DNA-sensing pathway CCL4/IL18/IL1B 3/16 0.001268
NOD-like receptor signaling pathway IL18/IL1B/TNF 3/16 0.001331
miR-320a Natural killer cell mediated cytotoxicity ICAM1/KIR2DL2/TNF 3/8 0.018267
African trypanosomiasis ICAM1/TNF 2/8 0.018267
Graft-versus-host disease KIR2DL2/TNF 2/8 0.018382
Malaria ICAM1/TNF 2/8 0.01936
RIG-I-like receptor signaling pathway TANK/TNF 2/8 0.029778
Antigen processing and presentation KIR2DL2/TNF 2/8 0.029845
Rheumatoid arthritis ICAM1/TNF 2/8 0.035321
Folate biosynthesis GCH1 1/8 0.072257
Asthma TNF 1/8 0.150454
Graft-versus-host disease GZMB/KIR2DL2/TNF 3/7 0.000379
miR-320b Graft-versus-host disease GZMB/KIR2DL2/TNF 3/7 0.000379
Natural killer cell mediated cytotoxicity GZMB/KIR2DL2/TNF 3/7 0.005999
Allograft rejection GZMB/TNF 2/7 0.008916
Type I diabetes mellitus GZMB/TNF 2/7 0.008916
Antigen processing and presentation KIR2DL2/TNF 2/7 0.019996
Hypertrophic cardiomyopathy (HCM) TNF/TPM1 2/7 0.019996
Dilated cardiomyopathy TNF/TPM1 2/7 0.020091
Folate biosynthesis GCH1 1/7 0.049597
Asthma TNF 1/7 0.117955
African trypanosomiasis TNF 1/7 0.117955
miR-93-5p Malaria IL6/ICAM1/THBS1 3/22 0.020688
Cytosolic DNA-sensing pathway IL6/CXCL10/NFKBIA 3/22 0.020688
NOD-like receptor signaling pathway NLRP3/IL6/NFKBIA 3/22 0.020688
RIG-I-like receptor signaling pathway CXCL10/NFKBIA/TANK 3/22 0.022958
Leishmaniasis IL1A/NFKBIA/PTGS2 3/22 0.022958
Rheumatoid arthritis IL6/ICAM1/IL1A 3/22 0.036896
Toll-like receptor signaling pathway IL6/CXCL10/NFKBIA 3/22 0.041751
African trypanosomiasis IL6/ICAM1 2/22 0.041751
Prion diseases IL6/IL1A 2/22 0.041751
Bladder cancer CDKN1A/THBS1 2/22 0.045977
Malaria IL6/ICAM1/THBS1 3/22 0.020688
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Fig. 6 Pathway enrichment of dysregulated mRNAs regulated by miRNAs. The pathways in dysregulated mRNAs predicted by miRNAs were
enriched by KEGG pathway enrichment analysis. “p adjust” represents the P value range. “Gene Ratio” represents the ratio of predicted target
gene number in total gene number of each relevant pathway
Fig. 7 Validation of predicted target genes of miRNAs. The expression of predicted target genes of miRNAs in PBMCs of smokers and COPD
patients was examined by qRT-PCR. Data are presented as 2(−σσCt) relative to β-actin. *P < 0.05, **P < 0.01, ***P < 0.001 compared with smokers by
Mann Whitney U test.
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